Clinical Trial Update: Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) [Phase 2]

View source ↗

Summary

Phase 2 trial of PXL065 for adrenomyeloneuropathy (AMN), a form of X-linked adrenoleukodystrophy, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenoleukodystrophy
• Adrenomyeloneuropathy

Drugs mentioned

• PXL065

Snippet

Sponsor: Poxel SA | Conditions: ALD (Adrenoleukodystrophy) | Phase 2 | Status: WITHDRAWN